Correlation Between VentriPoint Diagnostics and Manhattan Scients

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both VentriPoint Diagnostics and Manhattan Scients at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining VentriPoint Diagnostics and Manhattan Scients into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between VentriPoint Diagnostics and Manhattan Scients, you can compare the effects of market volatilities on VentriPoint Diagnostics and Manhattan Scients and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in VentriPoint Diagnostics with a short position of Manhattan Scients. Check out your portfolio center. Please also check ongoing floating volatility patterns of VentriPoint Diagnostics and Manhattan Scients.

Diversification Opportunities for VentriPoint Diagnostics and Manhattan Scients

0.5
  Correlation Coefficient

Very weak diversification

The 3 months correlation between VentriPoint and Manhattan is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding VentriPoint Diagnostics and Manhattan Scients in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Manhattan Scients and VentriPoint Diagnostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on VentriPoint Diagnostics are associated (or correlated) with Manhattan Scients. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Manhattan Scients has no effect on the direction of VentriPoint Diagnostics i.e., VentriPoint Diagnostics and Manhattan Scients go up and down completely randomly.

Pair Corralation between VentriPoint Diagnostics and Manhattan Scients

Assuming the 90 days horizon VentriPoint Diagnostics is expected to under-perform the Manhattan Scients. But the otc stock apears to be less risky and, when comparing its historical volatility, VentriPoint Diagnostics is 1.85 times less risky than Manhattan Scients. The otc stock trades about -0.04 of its potential returns per unit of risk. The Manhattan Scients is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  0.19  in Manhattan Scients on August 25, 2024 and sell it today you would lose (0.11) from holding Manhattan Scients or give up 57.89% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

VentriPoint Diagnostics  vs.  Manhattan Scients

 Performance 
       Timeline  
VentriPoint Diagnostics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days VentriPoint Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Manhattan Scients 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Manhattan Scients has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Manhattan Scients is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

VentriPoint Diagnostics and Manhattan Scients Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with VentriPoint Diagnostics and Manhattan Scients

The main advantage of trading using opposite VentriPoint Diagnostics and Manhattan Scients positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if VentriPoint Diagnostics position performs unexpectedly, Manhattan Scients can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Manhattan Scients will offset losses from the drop in Manhattan Scients' long position.
The idea behind VentriPoint Diagnostics and Manhattan Scients pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Complementary Tools

CEOs Directory
Screen CEOs from public companies around the world
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio